Microdosing LSD Analogues for Health & Longevity

Evidence Review created on 09/30/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Microdosing Lysergamides, LSD Analog Microdosing, LSD Prodrugs, Lysergamides, 1P-LSD, 1-Propionyl-LSD, 1cP-LSD, 1-Cyclopropionyl-LSD, 1V-LSD, 1-Valeroyl-LSD, 1B-LSD, 1-Butanoyl-LSD, 1D-LSD, 1T-LSD, 1S-LSD, ALD-52, 1A-LSD, 1-Acetyl-LSD, AL-LAD, ETH-LAD, LSZ

Motivation

LSD analogues are close chemical relatives of LSD (lysergic acid diethylamide), sold under code-like names that mimic the parent drug. Most are built so that the body converts them back into LSD itself. Microdosing means taking a small fraction of a full dose every few days, low enough to avoid hallucinations, with the aim of lifting mood, sharpening focus or supporting brain health. The analogues draw interest because they have been sold openly in some countries where LSD is banned.

The practice spread through self-experimenting professionals and online communities in the 2010s, long before controlled research existed. Researchers have since tested low doses of LSD against placebo in healthy adults, older adults and people with depression or attention problems, while the analogues themselves remain almost unstudied in people. Interest from a longevity angle rests on laboratory studies of how these compounds affect brain wiring and inflammation.

This review examines what controlled evidence shows about microdosing LSD and its analogues, the risks of repeated low doses and unregulated products, how dosing is practised, and how the evidence applies to health-focused adults.

Benefits - Risks - Protocol - Conclusion

This section lists expert and academic content that discusses LSD microdosing, LSD analogues, or the serotonin 2A receptor mechanism they share, in depth.

Note on priority experts: Rhonda Patrick’s FoundMyFitness content on psychedelics centres on full-dose psilocybin; its only microdosing item is a brief survey digest, not an in-depth treatment. Chris Kresser’s site mentions LSD microdosing only as a guest’s brief anecdote within a broader biohacking episode. Life Extension Magazine has no content on psychedelic microdosing. Lifespan.io’s related items are a short news brief on psychedelics for Alzheimer’s disease that mentions LSD in passing and a news summary of the same psilocybin mouse-lifespan study that the Peter Attia item appraises in more depth. None of these met the depth requirement, so four items are listed rather than five.

Grokipedia

  • Psychedelic microdosing

    Covers the practice, typical LSD doses and schedules, the gap between user reports and placebo-controlled trials, and cardiac and legal concerns.

  • Lysergamides

    Describes the compound class of LSD and its semisynthetic analogues such as 1P-LSD, LSZ and ETH-LAD: chemistry, serotonin 2A receptor pharmacology, history, and their emergence as novel psychoactive substances with varying legal status.

Examine

  • LSD

    Examine’s evidence page on LSD, the active compound the analogues release, summarizing its preliminary psychiatric evidence; no Examine page exists for the analogues themselves.

ConsumerLab

No ConsumerLab article on microdosing LSD analogues exists. ConsumerLab reviews dietary supplements and does not test controlled or grey-market psychoactive substances.

Systematic Reviews

These systematic reviews and meta-analyses cover psychedelic microdosing; none isolates the analogues, so each pools LSD, the compound the analogues release, with psilocybin.

Mechanism of Action

Most analogues sold (1P-LSD, 1cP-LSD, 1V-LSD, 1B-LSD, ALD-52) are “1-acyl” derivatives (carrying an extra chemical group on LSD’s position-1 nitrogen). They bind the serotonin 2A receptor (5-HT2A, the main target of classic psychedelics) only weakly, but blood and liver enzymes remove that group and release LSD — they are prodrugs (inactive forms converted into the active drug) (Halberstadt et al., 2020; co-authored by the founder of an analogue vendor). In two volunteers, oral 1P-LSD appeared in blood only as LSD, with near-complete conversion (Grumann et al., 2020).

LSD itself is a partial activator of 5-HT2A and also acts on the 5-HT1A, 5-HT2B (present on heart-valve cells) and 5-HT2C serotonin receptor subtypes and on dopamine receptors, so it is not selective. At microdoses it peaks after 1–1.5 hours, distributes moderately into tissues (about 33 L per 70 kg) and has a half-life near 3 hours (Holze et al., 2021; Morse et al., 2025; MindBio-funded). The liver clears it mainly through CYP2D6 (a drug-metabolizing enzyme), with the related enzymes CYP1A2, CYP2C9 and CYP3A4 contributing, to inactive 2-oxo-3-hydroxy-LSD.

Proposed benefits rest on neuroplasticity (growth of new neural connections) driven by 5-HT2A and mTOR (a cell-growth signalling hub), and on direct binding to TrkB (the receptor for BDNF, brain-derived neurotrophic factor — a protein supporting neuron growth) (Moliner et al., 2023). The competing view holds that sub-perceptual doses engage too few receptors and that reported effects reflect expectancy (Szigeti et al., 2021). Non-prodrug analogues (AL-LAD, ETH-LAD, LSZ) act directly and lack human data.

Historical Context & Evolution

LSD was synthesized in 1938 by Albert Hofmann at Sandoz and found to be psychoactive in 1943. Sandoz distributed it for psychiatric research, where low-dose “psycholytic” sessions were used as an aid to psychotherapy; ALD-52, the first 1-acyl analogue, was tested in humans in the 1950s and found roughly as potent. Prohibition in the late 1960s and the 1971 United Nations Convention on Psychotropic Substances halted most research, although some early low-dose studies had reported effects on perception and mood.

Microdosing re-emerged in the 2010s, popularized by psychologist James Fadiman’s schedule and adopted by technology workers seeking focus and creativity. From 2015, vendors sold 1P-LSD as an uncontrolled alternative to LSD; as countries banned each compound, new variants (1cP-LSD, 1V-LSD, 1D-LSD, 1T-LSD) followed.

Controlled research began in 2018–2019. Early surveys reported better mood and productivity, while placebo-controlled trials from 2019 onward found reliable acute effects but no lasting mood or cognitive gains. A self-blinding study suggested placebo explains most reported benefits (Szigeti et al., 2021); other researchers argue that conclusion is premature (Polito & Liknaitzky, 2022) because trials have been small, short and conducted mostly in healthy people. Much of this work comes from academic groups in Basel, Maastricht, Chicago and Auckland, several co-funded by the Beckley Foundation, a charity that advocates psychedelic research and has no product revenue, and by drug developers (Eleusis, MindMed, MindBio) with a commercial stake in LSD-based medicines. No analogue has been tested in a controlled human trial.

Expected Benefits

All controlled human data below come from LSD itself; the 1-acyl analogues release LSD in the body, so the findings apply to them only through that conversion.

High 🟩 🟩 🟩

No benefit reaches High: no health outcome has been replicated against placebo in more than one randomized trial of microdosed LSD, and no controlled human trial has tested any analogue.

Medium 🟩 🟩

Longer Sleep on the Night After Dosing

In a six-week randomized controlled trial (RCT, a study that assigns participants by chance to drug or placebo) of 80 healthy men taking 10 µg LSD every third day, wearable trackers recorded longer sleep on the night after each dose, with no sleep loss on dosing days (Allen et al., 2024; authors funded by MindBio Therapeutics, an LSD-microdose developer). Sleep stages and daytime activity did not change. The objective measure makes expectancy a less likely explanation, but this is a single trial in men using consumer-grade devices.

Magnitude: +24.3 minutes of sleep per post-dose night versus placebo; 95% CI (confidence interval, the range likely to contain the true effect) 10.3 to 38.3 minutes.

Low 🟩

Transient Dose-Day Mood and Energy Lift ⚠️ Conflicted

In a MindBio-funded home-dosing trial, 10 µg LSD raised daily happiness, energy and wellness ratings on dose days only (Murphy et al., 2023); laboratory doses of 13–26 µg left mood unchanged (de Wit et al., 2022). Net: a small same-day lift that does not accumulate.

Magnitude: Ratings rose on dose days only, at 10 µg with home dosing but not at 13–26 µg in the laboratory; the home-dosing trial reports the lift as a greater than 99% probability of improvement versus non-dose days, with no effect-size figure.

Reduced Anxiety ⚠️ Conflicted

Microdosers of psilocybin or LSD followed over four weeks reported less anxiety, but positive expectations predicted gains (Kaertner et al., 2021); pooled randomized trials found no reduction versus placebo (Meshkat et al., 2026). 1cP-LSD calmed shelter dogs only with behavioural training (Hernández-Álvarez et al., 2026). Net: no controlled human benefit.

Magnitude: Pooled randomized trials showed a between-group difference of −0.20 standard deviations (a standardized effect size; 0.2 is small, 0.5 medium) (95% CI −1.11 to 0.71), not significant; the observational study reports only within-group improvement.

Reduced Depressive Symptoms in Major Depression ⚠️ Conflicted

A MindBio-funded open-label trial (no placebo) gave 19 adults 6–20 µg LSD twice weekly for 8 weeks; depression scores fell and stayed lower for six months (Daldegan-Bueno et al., 2026). The 90-patient placebo-controlled follow-up did not beat placebo, per sponsor topline (a pipeline tracker summary). Net: no controlled benefit.

Magnitude: 59.5% reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS, a clinician-rated depression score) at 8 weeks in the open-label trial; no difference from active placebo (a comparison substance that mimics some drug sensations, here caffeine or methylphenidate) in the controlled trial.

Cold-Pain Tolerance ⚠️ Conflicted

A single 20 µg dose lengthened tolerance of 3 °C water and lowered pain ratings in 24 volunteers (Ramaekers et al., 2021); four 15 µg doses showed no effect in 48 volunteers (Cavarra et al., 2025). Net: any pain relief appears only at the top of the microdose range.

Magnitude: About 20% longer cold-water tolerance at 20 µg versus placebo; no effect at 5–15 µg.

Cluster Headache Relief

People with cluster headache (severe one-sided head pain recurring in weeks-long periods) report that infrequent, non-hallucinogenic LSD doses end attack periods and extend remission (Schindler et al., 2015; co-authored by nonprofit patient group Clusterbusters, whose members earn no revenue from it). Evidence is uncontrolled self-report surveys (Sewell et al., 2006).

Magnitude: In a 53-patient interview survey, 7 of 8 LSD users reported an ended cluster period and 4 of 5 a longer remission; no controlled trial has measured this.

Attention and Creativity Enhancement ⚠️ Conflicted

User surveys cite performance as the main motive, but 10 µg LSD left objective creativity tests unchanged (Murphy et al., 2025; MindBio-funded trial) and 20 µg twice weekly failed to beat placebo in adult attention-deficit/hyperactivity disorder (ADHD) (Mueller et al., 2025). Net: controlled data do not support enhancement.

Magnitude: ADHD symptom scores (Adult Investigator Symptom Rating Scale) fell 7.1 points on LSD versus 8.9 on placebo, with no difference between groups (trial sponsored by MindMed, a developer of LSD medicines).

Speculative 🟨

Neuroplasticity and Neurotrophic Signalling ⚠️ Conflicted

LSD grows neuron connections in cells and animals (Ly et al., 2018); plasma BDNF rose in one trial (Hutten et al., 2021), not another (Morse et al., 2025; MindBio-funded). Net: inconsistent human biomarker; preclinical basis.

Protection Against Neuroinflammation and Neurodegeneration

Cell and animal studies link 5-HT2A activation to lower inflammatory signalling and microglial (brain immune cell) activity (de Deus et al., 2025), motivating LSD development for Alzheimer’s disease. Basis: mechanistic only.

Lifespan Extension

LSD extended lifespan in Caenorhabditis elegans worms in a 2025 preprint (Carrilho et al., 2025); psilocybin extended survival in aged mice (Kato et al., 2025). Basis: animal data only.

Benefit-Modifying Factors

  • CYP2D6 genotype: People with no functional CYP2D6 (poor metabolizers) reach about 75% higher LSD exposure and stronger effects, so a nominal microdose acts like a larger dose (Vizeli et al., 2021).
  • Baseline mood: Adults with depressed mood (Beck Depression Inventory score ≥17) reported stronger positive effects from 26 µg LSD and a larger 48-hour drop in depression scores than non-depressed adults (Molla et al., 2024).
  • Baseline biomarkers: No blood biomarker predicts response. Baseline sleep duration and mood-scale scores are the practical reference points, since the measured effects (extra sleep, dose-day mood) are defined relative to them.
  • Sex: The sleep, mood and creativity trials enrolled men only; the attention trial included 42% women but reported no sex-stratified results (Mueller et al., 2025), leaving female-specific benefits largely untested.
  • Pre-existing conditions and medications: Long-term SSRI (selective serotonin reuptake inhibitor) antidepressants reduce 5-HT2A receptor density and can blunt effects; adults with attention deficits showed no benefit over placebo (Mueller et al., 2025).
  • Age: In adults aged 55–75, 10 µg lengthened reproduced time intervals without perceptible intoxication (Yanakieva et al., 2019; co-authored by Eleusis staff), showing older brains respond, though no age group has shown lasting benefit.
  • Expectancy: Positive baseline expectations predicted greater well-being gains in 81 naturalistic microdosers (Kaertner et al., 2021), so belief shapes perceived benefit.

Potential Risks & Side Effects

Controlled safety data again come from LSD; analogue-specific risks arise from product uncertainty and the absence of human data for newer compounds.

High 🟥 🟥 🟥

Acute Anxiety and Psychological Distress

In the largest home-dosing trial, anxiety led 4 of 40 men on 10 µg LSD to withdraw, versus none on placebo (Murphy et al., 2023). In the laboratory, 20 µg raised anxiety and somatization (physical complaints driven by distress) ratings (Ramaekers et al., 2021), and a systematic review ranks anxiety among the most frequent microdosing adverse events (Modzelewski et al., 2025). Episodes are dose-dependent and resolve within hours; two withdrawn participants had reduced CYP2D6 activity, suggesting higher exposure (Morse et al., 2025).

Magnitude: 10% of participants withdrew for anxiety on 10 µg LSD versus 0% on placebo over six weeks.

Perceptible Intoxication and Mild Dissociation

In one laboratory trial, 10 µg made volunteers rate themselves “under the influence”, and 20 µg added “bad drug effects” (Holze et al., 2021) and slightly increased derealization and depersonalization (feeling detached from surroundings or self) (Ramaekers et al., 2021). In a second trial, 26 µg produced LSD-like and stimulant-like effects (de Wit et al., 2022). Effects begin about an hour after dosing, peak near 2.5 hours and end by about 5 hours, which matters for driving and skilled work. 5 µg produced no detectable subjective effect.

Magnitude: 10 µg is the threshold dose for perceptible effects, which last about 4 hours (from 1.1 to 5.1 hours after dosing); dissociation ratings ranged from absent to mild.

Acute Blood Pressure Elevation

LSD 10 µg raised diastolic and 20 µg raised systolic and diastolic blood pressure in healthy volunteers (Ramaekers et al., 2021); repeated 15 µg doses raised systolic pressure on dosing days (Cavarra et al., 2025). The likely mechanism is narrowing of blood vessels through serotonin and adrenaline receptors, typical of ergot-derived compounds (drugs built on the chemical core of a grain fungus, which also narrow blood vessels). Readings stayed within the normal range; people with hypertension have not been studied.

Magnitude: Mean rises stayed below 10 mmHg at every time point after 10–20 µg, within the normal range in healthy adults.

Reduced Cognitive Control

A meta-analysis of 14 studies (1,614 participants) found microdosing lowered cognitive control (the ability to suppress automatic responses and stay on task), with no gains in other domains (Pinhas et al., 2026). LSD and psilocybin did not differ, and on-drug versus off-drug testing did not change the result. The effect is small but runs opposite to the performance claims that motivate most users.

Magnitude: Cohen’s d (a standardized effect size; 0.2 is small, 0.5 medium) of −0.34, 95% CI −0.62 to −0.06 (Özaydın & Canlan Özaydın, 2026).

Medium 🟥 🟥

No risk reaches Medium: beyond the replicated trial findings above, the remaining risks rest on conflicting trial data, a forensic case report, user and population surveys, or preclinical and computational data.

Low 🟥

Headache, Nausea, Fatigue and Insomnia ⚠️ Conflicted

Headache, nausea, fatigue and insomnia were the commonest drug-related adverse events on 20 µg LSD twice weekly, exceeding placebo (Mueller et al., 2025; MindMed-sponsored). Among older adults, 5–20 µg every fourth day caused no excess adverse events (Family et al., 2020; Eleusis-sponsored). Net: mild complaints emerge mainly at 20 µg.

Magnitude: 23 common treatment-related adverse events on 20 µg LSD versus 8 on placebo among 53 adults over 6 weeks; no excess over placebo at 5–20 µg in older adults.

Dose Uncertainty and Mislabelled Grey-Market Products

Analogues are sold as unregulated blotters, pellets or solutions. Forensic analysis found blotters labelled “1D-LSD” that contained 1T-LSD (Okada et al., 2024), and most surveyed microdosers did not know their dose (Hutten et al., 2019). The consequence can be an unintended full psychedelic experience or an untested compound.

Magnitude: A majority of 1,116 surveyed microdosers did not know the dose they took; no study reports a mislabelling rate for analogue products.

Hallucinogen Persisting Perception Disorder

Hallucinogen persisting perception disorder (HPPD, lasting visual disturbance after hallucinogen use) was reported by lifetime psychedelic users in a US population sample (Simonsson et al., 2025) but by no contemporary trial participant (Hinkle et al., 2024). Microdose data are absent.

Magnitude: 1.3% of lifetime (mostly full-dose) psychedelic users reported a clinician’s HPPD diagnosis.

Psychosis or Mania in Predisposed People

Among US adults, recent psychotic symptoms were highest in psychedelic users with a family history of psychotic or bipolar disorder (Simonsson et al., 2025). All microdosing trials excluded such people, so microdose-specific risk is unmeasured.

Magnitude: Symptoms were higher only in users with such a family history; the study reports only adjusted associations from statistical models, not rates, and the literature gives no incidence figure.

Speculative 🟨

Heart-Valve Disease from Chronic 5-HT2B Activation

LSD activates 5-HT2B, the receptor behind fenfluramine and pergolide valve damage (Tagen et al., 2023). Valves were unchanged in microdosed mice (Effinger et al., 2025) and 19 patients (Daldegan-Bueno et al., 2026); basis: mechanistic.

Unknown Toxicity of Newer Analogues

1V-LSD, 1D-LSD, 1T-LSD and 1S-LSD lack human data. Computer models flag heart-rhythm and DNA-damage alerts for some analogues (Jurowski et al., 2026). Basis: computational predictions only.

Risk-Modifying Factors

  • CYP2D6 genotype: Poor metabolizers have about 75% higher LSD exposure and longer effects (Vizeli et al., 2021); two anxiety withdrawals in the Auckland trial had reduced CYP2D6 activity (Morse et al., 2025).
  • Baseline blood pressure: Dosing-day rises are small in people with normal pressure but untested above 130/80 mmHg; pre-existing hypertension narrows the safety margin.
  • Baseline heart-valve status: Existing valve leakage, or prior exposure to valve-toxic drugs (fenfluramine, pergolide, cabergoline, methysergide), adds to the theoretical 5-HT2B risk of long-term dosing.
  • Sex: The largest safety trials enrolled men only; menstrual-cycle influences on anxiety and response are unstudied, which a premenstrual-disorder trial is beginning to address.
  • Pre-existing psychiatric conditions: Personal or family history of psychosis or bipolar disorder, panic disorder, and prior HPPD raise the likelihood of destabilization; anxiety-prone individuals account for most trial withdrawals.
  • Seizure disorders: Classic psychedelics do not appear to raise seizure risk in healthy people, but co-use with lithium may, and people with epilepsy have been excluded from studies (Soto-Angona et al., 2024).
  • Age: An Eleusis-sponsored trial (the company develops LSD for Alzheimer’s disease) found adults aged 55–75 tolerated 5–20 µg every fourth day without balance or cognitive impairment (Family et al., 2020); interaction risk rises with medication count.

Key Interactions & Contraindications

Prescription medications

  • Lithium — avoid (absolute contraindication): 47% of 62 online reports combining lithium with classic psychedelics described seizures (Nayak et al., 2021). No safe microdose is established; no mitigation is known.
  • SSRIs and SNRIs (serotonin-norepinephrine reuptake inhibitors; sertraline, escitalopram, venlafaxine) — caution: blunted effect because long-term use reduces the number of 5-HT2A receptors. Stopping them to microdose risks relapse and discontinuation symptoms; any change requires the prescriber.
  • Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) — monitor: mimic the poor-metabolizer state, raising LSD exposure and anxiety risk. Starting at half the usual dose offsets this.
  • MAOIs (monoamine oxidase inhibitors, an older antidepressant class; phenelzine, tranylcypromine) and tricyclics (also older antidepressants; amitriptyline, clomipramine) — caution: in self-reports, tricyclics intensified and MAOIs weakened LSD’s effects (Bonson & Murphy, 1996); MAOIs add serotonergic (serotonin-boosting) load, so response is unpredictable. Avoiding co-use mitigates this.
  • Antipsychotics and 5-HT2A blockers (quetiapine, olanzapine, risperidone, trazodone, mirtazapine) — caution (expected loss of effect): they occupy 5-HT2A; the blocker ketanserin cut LSD’s effect duration from 8.5 to 3.5 hours (Becker et al., 2023).
  • Ergot and triptan medicines (triptans are serotonin-activating migraine drugs; ergotamine, methysergide, cabergoline, sumatriptan) — caution: additive blood-vessel narrowing; methysergide and cabergoline add 5-HT2B valve risk. Same-day co-use is avoided.
  • Tramadol — caution: lowers the seizure threshold and adds serotonergic activity; risk of seizures or serotonin toxicity (agitation, tremor, fever from excess serotonin). Avoiding same-day use mitigates this.

Over-the-counter medications

  • Dextromethorphan (cough suppressants) — caution: serotonergic and cleared by CYP2D6; additive agitation and serotonin toxicity risk. Avoided on dosing days.
  • Decongestants (pseudoephedrine, phenylephrine) — monitor: additive blood-pressure rise on dosing days; a home cuff reading 2 hours after dosing identifies problematic rises.

Supplements

  • Serotonergic supplements (St. John’s wort, 5-HTP, L-tryptophan, SAMe) — caution: 5-HTP (5-hydroxytryptophan) and SAMe (S-adenosylmethionine) add serotonergic activity, theoretically risking serotonin toxicity. Separation from dosing days by 24 hours is common practice.
  • Stimulant supplements (caffeine, yohimbine, synephrine) — monitor: additive blood pressure, heart rate and anxiety effects. Reducing stimulant intake on dosing days mitigates this.

Other interventions

  • Cannabis — caution: raises anxiety and psychosis-like reactions when combined with psychedelics, especially in predisposed people. Avoiding same-day use is the usual mitigation.
  • Alcohol — monitor: masks perceptible effects and impairs judgement about further dosing; no pharmacokinetic interaction is described. Avoiding alcohol on dosing days mitigates this.
  • Other psychedelics (psilocybin, mescaline) — caution: cross-tolerance (one compound blunting the other’s effect) at 5-HT2A and stacking of intoxication; combining microdose schedules increases total serotonergic load and 5-HT2B exposure. Using one compound at a time avoids this.

Populations who should avoid Microdosing LSD Analogues:

  • Personal or first-degree family history of schizophrenia, other psychotic disorders, or bipolar I or II disorder
  • Current lithium therapy
  • Pregnancy or breastfeeding
  • Known valvular heart disease — moderate or greater regurgitation (valve leakage) or stenosis (valve narrowing) on echocardiography (heart ultrasound) — or prior use of valve-toxic drugs
  • Hypertension not controlled below 140/90 mmHg
  • Epilepsy or any prior unprovoked seizure
  • Prior hallucinogen persisting perception disorder
  • Age under 18 years
  • Safety-critical occupations (pilots, commercial drivers, heavy-machinery operators) on dosing days, and people subject to mandatory drug testing

Risk Mitigation Strategies

  • Low test dose: A first dose of about 5 µg LSD-equivalent on a free day, rising by 2–5 µg only if tolerated, limits anxiety and unintended intoxication.
  • Molar dose conversion: Accounting for analogue molecular weight and salt form (e.g., 10 µg LSD ≈ 12 µg 1P-LSD free base) prevents accidental overdosing or underdosing from treating label doses as LSD-equivalent.
  • Volumetric dosing: Harm-reduction guides describe dissolving one blotter in a measured volume (e.g., 100 µg in 10 mL distilled water = 10 µg/mL) to reduce dose variability from uneven blotter loading.
  • Independent drug checking: Laboratory analysis of each new batch detects mislabelled or substituted lysergamides before use.
  • Dosing-day blood pressure checks: Readings about 2 hours after the first three doses, then weekly; values above 140/90 mmHg are a common stopping threshold, limiting cardiovascular strain.
  • Limited cumulative exposure: Cycles of 4–8 weeks with 2–4 week breaks, plus echocardiography at baseline and every 12 months for cumulative use beyond 3 months, address the theoretical heart-valve risk.
  • Pharmacogenetic screening: CYP2D6 genotyping before starting identifies poor metabolizers, for whom half-dose starts limit exaggerated exposure and anxiety.
  • Medication review: Screening for lithium, CYP2D6 inhibitors, antipsychotics and tramadol before starting prevents seizures, blunting and excess exposure.
  • No driving at peak: Avoiding driving and safety-critical tasks for 6 hours after each dose mitigates impaired cognitive control and intoxication.

Therapeutic Protocol

  • Community protocol (Fadiman): One dose every third day (“one day on, two days off”) for 4–10 weeks, popularized by psychologist James Fadiman; doses approximate one-tenth of a full dose, i.e., 6–20 µg LSD.
  • Clinical-trial regimens: Auckland (Suresh Muthukumaraswamy): 10 µg every third day for 6 weeks (Murphy et al., 2023); Basel–Maastricht (Matthias Liechti): 20 µg twice weekly (Mueller et al., 2025); depression: 6–20 µg twice weekly (Daldegan-Bueno et al., 2026).
  • Analogue dose equivalence: Because 1-acyl analogues are heavier than LSD, 10 µg LSD corresponds to roughly 11–13 µg of ALD-52, 1P-LSD, 1cP-LSD or 1V-LSD free base, more for tartrate salts, assuming complete conversion.
  • Alternative schedules (Stamets and as-needed): A 4-days-on, 3-days-off schedule popularized by mycologist Paul Stamets for psilocybin, and “as-needed” dosing, are also used; neither has controlled data for LSD or its analogues.
  • Supervised full-dose paradigm: Psychiatric trials (e.g., Basel, MindMed) give one or two 100–200 µg LSD doses with therapy — a separate paradigm with its own evidence, not interchangeable with microdosing.
  • Best time of day: Morning dosing is standard; effects begin after about 1 hour, peak near 2.5 hours and end by about 5 hours, so evening doses risk delayed sleep onset.
  • Half-life: LSD’s half-life at microdoses is about 2.7–3.1 hours; analogues add a conversion step, and after 1P-LSD the terminal LSD half-life was about 6.4 hours in two volunteers (Grumann et al., 2020).
  • Single versus split dosing: Every trial used a single dose; splitting a microdose has no pharmacological rationale given the short half-life and threshold-dependent effects.
  • Genetic polymorphisms: CYP2D6 poor metabolizers (roughly 5–10% of people of European ancestry) have about 75% higher exposure; half-dose starts are used in pharmacogenetically informed practice.
  • Sex-based differences: No sex-specific dosing exists; sleep and mood trials enrolled men only, and luteal-phase (pre-menstrual) dosing is being tested in premenstrual disorders.
  • Age: Adults up to 75 tolerated 5–20 µg every fourth day (Family et al., 2020); older adults taking several medications typically start at the low end after an interaction review.
  • Baseline biomarkers: Elevated baseline blood pressure favours doses of 10 µg or less; people with depressed mood at baseline feel stronger effects at a given dose.
  • Pre-existing conditions: Anxiety disorders favour 5 µg starts; long-term antidepressant use blunts response, tempting higher doses that increase variability; psychotic or bipolar histories exclude use.

Discontinuation & Cycling

  • Short-term use: Microdosing is practised in time-limited cycles of 4–10 weeks rather than lifelong; no controlled data address use beyond 8 weeks.
  • Withdrawal effects: No physical dependence or withdrawal syndrome is described for LSD or its analogues; trials stopped dosing abruptly without reported rebound effects.
  • Tapering: Not required pharmacologically; stopping at the end of a cycle is standard practice.
  • Tolerance and cycling: Daily LSD produces rapid 5-HT2A tolerance; twice-weekly dosing showed no tolerance across 16 doses (Daldegan-Bueno et al., 2026). Breaks of 2–4 weeks between cycles are conventional.
  • Stopping triggers: Persistent anxiety, new visual disturbances, sustained blood pressure rise, or a newly detected heart murmur are the commonly cited reasons to stop.

Sourcing and Quality

  • No regulated source: No pharmaceutical or compounding-pharmacy supply of any LSD analogue exists; products are grey-market blotters, pellets or solutions sold as “research chemicals” where not yet controlled.
  • Identity uncertainty: Label–content mismatches are documented (blotters sold as 1D-LSD contained 1T-LSD; Okada et al., 2024), and new variants appear whenever older ones are banned, so the compound in a product is often unverified.
  • Testing: Ehrlich reagent confirms an LSD-family compound but cannot distinguish LSD from its analogues or measure dose; laboratory drug-checking services (e.g., Energy Control, DrugsData) identify compounds.
  • Stability: Lysergamides degrade with light, heat and moisture; the added acyl group can break off, turning the compound into LSD, in alcohol solvents under heat, ALD-52 more readily than 1P-LSD (Zhang et al., 2023).
  • Salt form: Hemitartrate salts contain less active base per microgram than free base, so labels must state the form for accurate conversion.
  • Reference-grade alternative: Pharmaceutical-grade LSD (e.g., LSD D-tartrate, DT120 from MindMed, now Definium Therapeutics) is available only within registered clinical trials.

Practical Considerations

  • Time to effect: Acute effects appear within about an hour; extra sleep appears the following night; depression scores fell over 8 weeks in an open-label trial (Daldegan-Bueno et al., 2026); healthy adults showed no lasting change after 6 weeks.
  • Common pitfalls: Treating analogue label doses as LSD-equivalent, ignoring salt form, dosing daily, combining with lithium, attributing expectancy effects to the drug, and driving at peak effect.
  • Regulatory status: LSD is US Schedule I and controlled under a 1971 United Nations treaty. Analogues are controlled in Germany (1P-LSD since 2019, 1V-LSD since 2023) and Japan, fall under the UK Psychoactive Substances Act 2016, and risk prosecution under the US Federal Analogue Act.
  • Drug testing: Analogues convert to LSD, so specialized LSD assays can return positive results; standard workplace panels rarely include LSD.
  • Cost and accessibility: Products cost little per dose but are legally precarious and unverified; legal access to LSD itself is limited to clinical trials.
  • Payer and developer incentives: Patented LSD (e.g., DT120, in phase 3 trials) would cost far more than generic antidepressants, so insurers and health systems have an incentive to favour cheaper care, a potential guideline bias; unpatentable analogues attract no trial sponsor, skewing research funding.

Interaction with Foundational Habits

  • Sleep: Potentiating. In one trial (Allen et al., 2024), 10 µg LSD lengthened sleep by about 24 minutes the following night without changing sleep stages, suggesting increased sleep need rather than disruption. Morning dosing keeps the roughly 5-hour effect window away from bedtime; evening doses risk delayed sleep onset.
  • Nutrition: Indirect. No nutrient depletion is known. Food likely slows absorption and delays onset, so trials dosed in a standardized fasting or light-meal state; alcohol and high-caffeine intake add to anxiety and blood-pressure effects on dosing days.
  • Exercise: Indirect, untested. Dosing-day blood pressure rises add to exercise-induced rises, and reduced cognitive control may matter for technical sports; no study has measured training adaptation, so many practitioners keep intense sessions off dosing days or schedule them after the 5-hour window.
  • Stress management: Direct. Full doses raise cortisol, and microdoses provoke anxiety in some people; pre-existing stress and negative expectations increase distress. Meditation, calm settings (“set and setting”) and avoiding high-pressure tasks on dosing days are the usual supporting practices.

Monitoring Protocol & Defining Success

Baseline testing before a first cycle establishes cardiovascular, psychiatric and pharmacogenetic starting points: a seated blood pressure series, resting heart rate, a validated depression and anxiety questionnaire, one to two weeks of wearable sleep data, CYP2D6 genotyping, and an echocardiogram for anyone planning cumulative use beyond 3 months or with a heart murmur. A short computerized attention task gives a personal cognitive-control reference.

Ongoing monitoring follows a fixed cadence: blood pressure about 2 hours after each of the first three doses, then weekly during the cycle; mood and anxiety questionnaires at weeks 2, 4 and 8; continuous sleep tracking throughout; the attention task at week 4 and cycle end; and echocardiography every 12 months while cumulative use continues. Success means measurable improvement in the targeted outcome without blood pressure, anxiety or cognitive-control deterioration.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure (home cuff) Below 120/80 mmHg; dosing-day rise under 10 mmHg Detects dose-related rises Conventional US guideline normal is under 130/80 mmHg; seated, after 5 minutes’ rest, about 2 hours post-dose; pair with heart rate
Resting heart rate 50–70 beats per minute Flags stimulant-like strain Conventional range 60–100; morning, before caffeine
Echocardiogram (heart ultrasound) No more than trace valve regurgitation, unchanged from baseline Screens for valve damage No established microdosing target; change from own baseline is the key signal; baseline and every 12 months with cumulative use beyond 3 months
CYP2D6 genotype Normal metabolizer Predicts exposure One-time test; poor or intermediate metabolizers start at half dose; pair with medication review for CYP2D6 inhibitors
PHQ-9 depression score 0–4 Tracks mood effect PHQ-9 = Patient Health Questionnaire-9; conventional cut-off for “minimal” is under 5; same time of day each assessment
GAD-7 anxiety score 0–4 Detects anxiety adverse effects GAD-7 = Generalized Anxiety Disorder-7 questionnaire; conventional “minimal” is under 5; complete on a non-dosing day
Sleep duration (wearable) 7–9 hours Tracks sleep effect No established microdosing target; track change from own 1–2 week baseline, comparing post-dose and other nights
Cognitive-control task (e.g., Stroop or go/no-go app) No decline from own baseline Detects impaired inhibition No established target; test off-drug at the same time of day to avoid practice and timing effects

Qualitative markers:

  • Energy, mood and sense of connection on dosing versus non-dosing days
  • Focus and error rate at work
  • Anxiety, restlessness or somatic discomfort within 5 hours of dosing
  • Visual disturbances persisting beyond the dosing day
  • Sleep quality and morning alertness
  • Motivation for healthy habits (exercise, diet, social contact)

Emerging Research

  • Premenstrual disorders trial: Microdosing LSD in women with premenstrual disorders (NCT07189299); 150 participants, 10 µg LSD daily or every other day in the late luteal phase for three cycles versus placebo; primary endpoint: Daily Record of Severity of Problems score. First trial focused on women.
  • Shorter-acting analogue: Pharmacokinetics of didehydro-LSD compared with LSD (NCT07309471); 24 healthy volunteers, crossover design (each participant receives every treatment in turn) versus LSD and placebo; primary endpoints: effective dose, half-life and effect duration. It is the first controlled human study of a new LSD analogue.
  • Receptor occupancy imaging: LSD occupancy of the serotonin 2A receptor (NCT05953038); 40 participants, positron emission tomography (brain imaging) relating dose to receptor occupancy — could show whether microdoses engage enough receptors to act beyond placebo.
  • Low-dose LSD in depression: Mood effects of serotonin agonists in depression (NCT07017478); 41 participants, 26 µg LSD versus placebo, mood, effort-for-reward and sleep outcomes; completed, results pending.
  • Active-placebo depression trial: LSDDEP2 (no NCT ID; ACTRN12624000128594), a completed phase 2b trial co-funded by MindBio Therapeutics; 90 patients with major depression, 8 weeks of twice-weekly 4–20 µg LSD versus active placebo, primary endpoint MADRS (Daldegan-Bueno et al., 2024). Topline showed no superiority (a pipeline tracker summary); full publication pending.
  • Non-hallucinogenic LSD analogues: 2-Bromo-LSD lacks 5-HT2B activation yet promotes neuronal growth in rodents (Lewis et al., 2023; co-authored by developer BetterLife Pharma), and the designed analogue JRT showed similar properties (Tuck et al., 2025; co-authored by developer Delix Therapeutics), potentially bypassing both hallucination and valve risk.
  • Cardiac safety: Chronic low-dose LSD caused no ventricular or valve remodelling (structural thickening or damage) in mice, unlike fenfluramine (Effinger et al., 2025); reviewers call for echocardiographic monitoring in longer human studies (Rouaud et al., 2024).
  • Longevity signals: LSD extended worm lifespan in a preprint (Carrilho et al., 2025); mammalian lifespan and human aging-biomarker studies of LSD or any analogue have not been reported.
  • Evidence weakening the case: Pooled trials in healthy adults show no benefit beyond placebo (Meshkat et al., 2026), and reanalysis of the self-blinding study suggests broken blinding can create false positives (Szigeti et al., 2023).

Conclusion

Microdosing LSD analogues means taking small, repeated doses of compounds that mostly turn into LSD in the body. Limited human data suggest the common ones add nothing to LSD’s effects; others act on their own and are untested. What they add is uncertainty: unregulated, sometimes mislabelled products and newer variants never studied in people.

For health-focused adults, controlled evidence on LSD itself is modest. Small doses produce short-lived changes: slightly longer sleep the next night and noticeable effects at the upper end of the dose range; a same-day lift in mood appeared in some trials, not others. Lasting improvements in mood, focus or creativity have not held up against placebo in healthy people, and early signs of benefit in depression, seen without a comparison group, were not confirmed. Claims about brain renewal, inflammation and lifespan rest on cell and animal work.

The main risks are dose-day anxiety, feeling intoxicated, small blood-pressure rises and a slight drop in the ability to stay on task. Serious dangers concentrate in specific groups: people taking lithium, people with a personal or family history of psychosis or bipolar disorder, and people with heart-valve problems, where long-term effects remain unknown.

The evidence base is small, short and mostly in healthy men. Much of it comes from groups backed by companies developing patented LSD medicines, or by an advocacy charity and a patient group that earn no product revenue. Key analogue studies were co-written by a vendor’s founder. The overall picture is uncertain rather than settled.

Top - Benefits - Risks - Protocol